These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 16240706)

  • 1. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure measures applied to the bioequivalence of two sustained release formulations of bupropion.
    Midha KK; Rawson MJ; McKay G; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 May; 43(5):244-54. PubMed ID: 15906590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory and study conditions for the determination of bioequivalence of highly variable drugs.
    Endrenyi L; Tothfalusi L
    J Pharm Pharm Sci; 2009; 12(1):138-49. PubMed ID: 19470298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
    Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the bioequivalence of highly-variable drugs and drug products.
    Tothfalusi L; Endrenyi L; Midha KK; Rawson MJ; Hubbard JW
    Pharm Res; 2001 Jun; 18(6):728-33. PubMed ID: 11474774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
    Lechat P
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence approaches for highly variable drugs and drug products.
    Haidar SH; Davit B; Chen ML; Conner D; Lee L; Li QH; Lionberger R; Makhlouf F; Patel D; Schuirmann DJ; Yu LX
    Pharm Res; 2008 Jan; 25(1):237-41. PubMed ID: 17891552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scaling or wider bioequivalence limits for highly variable drugs and for the special case of C(max).
    Tothfalusi L; Endrenyi L; Midha KK
    Int J Clin Pharmacol Ther; 2003 May; 41(5):217-25. PubMed ID: 12776813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.
    Tothfalusi L; Endrenyi L; Arieta AG
    Clin Pharmacokinet; 2009; 48(11):725-43. PubMed ID: 19817502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribability and switchability of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    J Control Release; 1999 Nov; 62(1-2):33-40. PubMed ID: 10518632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs.
    Boddy AW; Snikeris FC; Kringle RO; Wei GC; Oppermann JA; Midha KK
    Pharm Res; 1995 Dec; 12(12):1865-8. PubMed ID: 8786957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limits for the scaled average bioequivalence of highly variable drugs and drug products.
    Tothfalusi L; Endrenyi L
    Pharm Res; 2003 Mar; 20(3):382-9. PubMed ID: 12669957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.
    Davit BM; Chen ML; Conner DP; Haidar SH; Kim S; Lee CH; Lionberger RA; Makhlouf FT; Nwakama PE; Patel DT; Schuirmann DJ; Yu LX
    AAPS J; 2012 Dec; 14(4):915-24. PubMed ID: 22972221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence: switchability and scaling.
    Midha KK; Rawson MJ; Hubbard JW
    Eur J Pharm Sci; 1998 Apr; 6(2):87-91. PubMed ID: 9795020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.
    Bialer M; Sussan S; Abu Salach O; Danenberg HD; Ben-David J; Gibor Y; Laor A
    J Pharm Sci; 1995 Oct; 84(10):1160-3. PubMed ID: 8801328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limits of 80%-125% for AUC and 70%-143% for Cmax. What is the impact on bioequivalence studies?
    Hauck WW; Parekh A; Lesko LJ; Chen ML; Williams RL
    Int J Clin Pharmacol Ther; 2001 Aug; 39(8):350-5. PubMed ID: 11515710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a scaling approach for the bioequivalence of highly variable drugs.
    Haidar SH; Makhlouf F; Schuirmann DJ; Hyslop T; Davit B; Conner D; Yu LX
    AAPS J; 2008 Sep; 10(3):450-4. PubMed ID: 18726698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.